Although androgen withdrawal can control prostate cancer for long periods, there remains a substantial unmet clinical need when faced with patients whose tumour becomes androgen independent. Many of these patients rapidly develop hormone refractory and metastatic prostate cancer. The prognosis for these patients is very poor – less than 50% survive beyond 2 years. VAL201 selectively inhibits androgen, oestrogen and epithelial growth factor dependent DNA synthesis. In pre-clinical studies carried out in collaboration with the University of Oxford, VAL201 prevented cancerous growth in live models; the response has been shown to be dose dependent.
Furthermore, the treated models remained fertile and produced normal offspring. In contrast to traditional therapies, VAL201 appears to leave other hormone induced activities working normally, therefore reducing side effects such as lowered sexual function and infertility. As such, VAL201 showed effect in pre-clinical studies for superior therapeutics in the treatment of hormone induced noncancerous cell growth as seen in endometriosis.
ValiPharma is currently in Phase 1/2 clinical trials for VAL201’s prostate cancer programme at University College London Hospital (UCLH) Clinical Research Facility having been accepted by the Medicines & Healthcare products Regulatory Agency (MHRA).